Jefferies Pulmonologist Survey Supports United Therapeutics' (UTHR) Tyvaso Franchise Potential

March 23, 2022 8:14 AM EDT Send to a Friend
Jefferies analyst Eun Yang reiterated a Buy rating and $223.00 price target on United Therapeutics Corp. (NASDAQ: UTHR) after conducting ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login